The potential of antidiabetic thiazolidinediones for anticancer therapy
- 17 August 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 15 (9) , 1039-1049
Abstract
(2006). The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opinion on Investigational Drugs: Vol. 15, No. 9, pp. 1039-1049. doi: 10.1517/13543784.15.9.1039Keywords
This publication has 75 references indexed in Scilit:
- Troglitazone Inhibits Cyclin D1 Expression and Cell Cycling Independently of PPARγ in Normal Mouse Skin KeratinocytesJournal of Investigative Dermatology, 2004
- Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancersNuclear Medicine Communications, 2004
- PPARγ signaling exacerbates mammary gland tumor developmentGenes & Development, 2004
- Thiazolidinediones: metabolic actions in vitroDiabetologia, 2002
- Differential Regulation of Vascular Endothelial Growth Factor Expression by Peroxisome Proliferator-activated Receptors in Bladder Cancer CellsJournal of Biological Chemistry, 2002
- Regulation of Gene Expression by Activation of the Peroxisome Proliferator-Activated Receptor γ with Rosiglitazone (BRL 49653) in Human AdipocytesBiochemical and Biophysical Research Communications, 1999
- Terminal Differentiation of Human Breast Cancer through PPARγMolecular Cell, 1998
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Retinoid receptors in human lung cancer and breast cancerMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996
- Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factorCell, 1994